A Chat with Anat

• From the Community, For the Community

  In this special episode, I am joined by two of my long-time friends and collaborators, Professor Jean-François Korobelnik, my Co-chair of the Vision Academy and Professor of Ophthalmology at the University Hospital of Bordeaux, France, and Dr Jane Barratt, my Co-chair of the Barometer Program, and former Secretary General and Global Advisor at the International Federation of Ageing.Tune in as we unpack the statement “From the Community, For the Community,” exploring how collaborations between academia, industry, and non-governmental organizations shape clinical practice and influence policy, with practical advice for listeners keen to get involved in such initiatives, and drive meaningful change.This episode was recorded live at the Joint Vision Academy Steering Committee and Barometer Leadership Coalition Meeting in Rome in February 2025. To learn more about these programs, find your country’s representative, and access the important materials and training resources for clinicians and patients to improve patient-focused care and clinical practice, visit the Vision Academy Program website and nAMD Barometer Program website.If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures:Professor Anat LoewensteinConsultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant.Professor Jean-François KorobelnikConsultant: AbbVie, Adverum, Apellis, Bayer, Boehringer Ingelheim, Carl Zeiss Meditec, EyePoint, Ocular Therapeutix, Roche, SeaBeLife, and Théa; Member of data safety monitoring board: Alexion, Novo Nordisk, and Opthea.Dr Jane BarrattConsultant: Bayer.August 2025 | PP-PF-OPHT-ALL-0231-1This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

  --------  

  23:13

  --------

  23:13
• The Hot Seat

  In this special episode, the roles have been reversed! Your host is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at the University of Manchester in the United Kingdom, who asked me questions sent in by my retinal community colleagues.Tune in to hear how I balance my busy career with my well-being, the pep talks I give to nervous first-time patients and trainees, myths about retinal disease I’d like to erase forever, and even an embarrassing moment in my career! This episode was recorded live at the Joint Vision Academy Steering Committee and Barometer Leadership Coalition Meeting in Rome. To learn more about these programs and access the important materials and training resources for clinicians and patients to improve patient-focused care and clinical practice, visit the Vision Academy Program website and nAMD Barometer Program website.If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures:Professor Anat LoewensteinConsultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant.Professor Tariq AslamGrants, speaker fees, and travel: Bayer, Boehringer Ingelheim, Canon, Heidelberg, Novartis, Roche, Thea, and Topcon.July 2025 PP-PF-OPHT-ALL-0230-1This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

  --------  

  25:25

  --------

  25:25
• Monitoring the fellow eye in nAMD

  My guest for this special episode is Professor Paolo Lanzetta, Chair of the Department of Ophthalmology at the University of Udine, Italy. In this episode, Paolo and I explore the importance of monitoring the fellow eye of patients with nAMD. We also discuss methods and techniques for early detection of disease, the difference in monitoring for patients with DME, and the Vision Academy’s evidence-based guidance on monitoring the fellow eye. To learn more about monitoring the fellow eye in patients with nAMD, read the Vision Academy Viewpoint, the Vision Academy slide deck, and the Vision Academy publication on current concepts and modalities for monitoring the fellow eye in nAMD.  For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites.If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures:Professor Anat LoewensteinConsultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, VoiantProfessor Paolo LanzettaConsultant: Aerie, Allergan, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, I-Care, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche May 2025 PP-PF-OPHT-ALL-0219-1Further information on topics discussed in this podcast:Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009 Jan;116(1):57─65.e5.Chew JK, Zhu M, Broadhead GK, Luo K, Hong T, Chang AA. Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes. Ophthalmologica. 2017 Jan 1;238(1-2):23–30.Downey L, Acharya N, Devonport H, Gale R, Habib M, et al. Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. BMJ Open Ophthalmol. 2021 Apr 27;6(1):e000696.Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA StuThis podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

  --------  

  19:35

  --------

  19:35
• Choosing the right regimen for patients with nAMD

  My guest for this special episode is Prof. Jean- François Korobelnik from the Department of Ophthalmology at the University Hospital, and at CHU Bordeaux, in Bordeaux, France. In this episode, Jean-François and I explore the importance of choosing the right regimen for our patients with nAMD. We discuss the evidence we can gather from clinical trials, and the lessons we learn from patients we see during clinical practice. We also explore the algorithm developed by the Vision Academy to choose the best regimen for patients.To learn more about how to choose the best treatment regimens to optimize outcomes for patients with nAMD, read the Vision Academy Viewpoint, and the accompanying slide deck. Please also visit the Vision Academy website. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites.If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures:Professor Anat LoewensteinConsultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, Voiant.Professor Jean- François KorobelnikConsultant: Abbvie, Adverum, Apellis, Bayer, Boehringer-Ingelheim, Carl Zeiss Meditec, Eyepoint Pharma, Ocular Therapeutix, Roche, SeaBeLife, Thea; member of the data safety monitoring board or advisory board for Alexion, Novo Nordisk, and Opthea.April 2025 PP-PF-OPHT-ALL-0215 -1Further information on topics discussed in this podcast:Teo KYC, Eldem B, Joussen A, Koh A, Korobelnik JF, Li X, Loewenstein A, Lövestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodríguez F, Wong D, Wu L, Zur D, Zarranz-Ventura J, Mitchell P, Chaudhary V, Lanzetta P. Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration. Eye (Lond). 2024. doi: 10.1038/s41433-024-03370-0. Gemenetzi M, Patel PJ. A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Ophthalmol Ther. 2017;6:79-92. Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness Study Group. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related maculThis podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

  --------  

  12:47

  --------

  12:47
• Revolutionizing holistic patient care: Innovations and technologies

  My guest for this special episode is Dr. John Kitchens, Vitreoretinal Surgeon with Retina Associates of Kentucky in the USA. In this episode, John and I explore the importance of holistic patient care. We also highlight the latest advances in home monitoring technologies in retinal disease, and how artificial intelligence (AI) can be used to aid in disease monitoring and optimization of clinic organization. To learn more about the current status of AI in screening, diagnosing and managing retinal diseases, read the Vision Academy Viewpoint, and the Vision Academy retinal expert consensuses by clicking here or here. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures:Professor Anat Loewenstein- Consultant: Consultant for 4DMT, Abbvie, Alkeus, Annexon, Apellis, Astellas, Bayer health care, Beyeonics, Eyepoint, J & J, NotalVision, Novartis, Ocular Therapeutics, Ocuphire Pharma, Ocuterra, Oculis, Opthea, Oxurion, Roche, Syneos.Dr. John Kitchens - Consultant: Alcon, Allergan, Alimera, Apellis, Astellas, Bayer, Biogen, Bausch + Lomb, Genentech, Kodiak Bioscience, Notal Vision, Optos, Oculus, Outlook, Regeneron, Roche, and Zeiss. Speaker: Alcon, Bayer, Genentech, and Regeneron. Owns stock in Regeneron.Further information on topics discussed in this podcast:Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417–1436.The Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni JP, et al. Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4. JAMA Ophthalmol. 2013;131:843–850. Anguita R, Ferro Desideri L, Loewenstein A, et al. The digital age in retinal practice. Int J Retina Vitreous. 2024 Sep 26;10:67. doi: 10.1186/s40942-024-00580-2. January 2025 PP-PF-OPHT-ALL-0199-1This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

  --------  

  17:46

  --------

  17:46

Więcej Nauka podcastów

Trendy w podcaście Nauka

O A Chat with Anat